Liquid Biopsies :
There are two types of liquid biopsy (which is actually a biopsy as they test blood that does not require biopsy of tissue): Circulating tumors are cell assay or cell-free circulating tumor DNA test. These methods replicate a non-invasive alternative to invasive biopsies that evaluate mutations in cancer and provide personalized treatment plans. In addition, because cancer is a skewed genetic disease, and excisional biopsies provide only a snapshot in the time of the rapid few, dynamic genetic changes occurring in the tumors, liquid biopsies provide few benefits over tissue biopsy-based genomic why. In addition, excisional biopsies are invasive, cannot be used repeatedly, and ineffective in understanding the tumor progression and dynamics of metastasis. By detecting and enhancing genomic changes in CTCs and cell-free DNA, blood biopsy can provide real-time information on the stage of tumor progression, treatment effectiveness, and cancer metastasis risk.  This technological development can lead to possible diagnosis and manage cancer from a traditional biopsy rather than repeated blood tests.
Circulating tumor cell trials are under development by the Epic Science. Analysis of test-operated tumor cells (CTCs) of individual CTCs demonstrated a high level of diversity seen on single-cell level for both protein expression and protein localization and CTCs both primary biopsy and transformation reflected in metastatic sites. Analysis of cell-free circulating tumor DNA (coda) is that there is almost 100 times more cell-free DNA than there is an advantage on the assay in the circulating tumor cells in DNA circulating tumor cells. These tests analyze the fragmentation of tumor cell DNA that is constantly shed by the tumor in the blood. Companies offering coda next generation sequencing tests include personal genome diagnosis and protecting health. These tests are being used in widespread use when there is insufficient material for a tissue biopsy DNA test or when it is not safe to do an invasive biopsy procedure, but according to a latest report of results according to 15,000 advanced cancer patients On the sequence, the Home Guard’s health test was conducted.
Through the study of 846 patients with 15 different types of cancer in 24 institutions, the body was able to detect the presence of cancer DNA in the body. They found tumor-DNA in the blood of more than 80 percent of patients with about 47 percent of those with metastatic cancer and localized tumors. The test does not indicate the tumor site (s) or other information about the tumor.
The test did not produce false positive. It is also useful to assess such trials that malignant cells live in patients whose tumors are removed from surgery. Expect to fall down to 30 percent because some tumor cells live. About the initial study, half the patients who later reflex, then identified without false positive. One of the potential uses is to track specific DNA mutations a tumor driving. Many new cancer drugs block specific molecular processes. Such tests could allow easy targeting of therapy for tumors.
Also Read :